首页 > 最新文献

Cancer diagnosis & prognosis最新文献

英文 中文
The Prognostic Significance of Plasma Beta2-Glycoprotein I Levels in Hepatocellular Carcinoma Patients. 肝细胞癌患者血浆 Beta2-Glycoprotein I 水平的预后意义
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10389
Tsung-Jen Hsieh, Hung-Wei Pan, Yu-Yan Lan, Guan-Ying Hua, Yao-Chun Hsu, Wen-Chin Chiu

Background/aim: Beta2-glycoprotein I (β2-GPI) is a plasma glycoprotein with multiple physiological functions, but its relationship with hepatocellular carcinoma (HCC) is still poorly understood. HCC is one of the most common forms of liver cancer and is a leading cause of cancer-related death worldwide. This study aimed to investigate the association between β2-GPI and liver cancer and further validate its potential as a biomarker for HCC.

Patients and methods: Thirty-six patients diagnosed with HCC at the Division of Gastroenterology and Hepatology, E-Da Hospital, Taiwan, were included in the study. The expression levels of β2-GPI in plasma specimens from patients with HCC were determined by enzyme immunoassay and analyzed in relation to clinicopathological variables using the Chi-square test or Fisher's exact test. The predictive significance of β2-GPI for both overall survival (OS) and disease-free survival (DFS) was assessed using Kaplan-Meier estimates, and the statistical significance of differences was evaluated through the log-rank test. Cox proportional hazards regression models were used to evaluate the association between OS/DFS time and clinicopathological characteristics.

Results: Results: Plasma β2-GPI levels were significantly lower in patients with HCC compared to non-cancer controls and significantly correlated with aspartate aminotransferase (AST) levels of HCC. High plasma β2-GPI levels were significantly associated with better OS and DFS in HCC patients. Furthermore, in multiple variates analyses, OS was found to be significantly better in HCC patients with higher plasma β2-GPI expression.

Conclusion: Elevated levels of β2-GPI protein in the plasma of HCC patients were identified as an independent factor predictive of improved OS and DFS. Activating β2-GPI in individuals at high risk could serve as a promising way for mitigating the progression of HCC.

背景/目的:β2-糖蛋白 I(β2-GPI)是一种具有多种生理功能的血浆糖蛋白,但人们对它与肝细胞癌(HCC)的关系仍知之甚少。HCC 是最常见的肝癌形式之一,也是全球癌症相关死亡的主要原因。本研究旨在探讨β2-GPI与肝癌之间的关系,并进一步验证其作为HCC生物标志物的潜力:研究纳入了台湾义大医院消化内科和肝病科的 36 名确诊为 HCC 的患者。采用酶联免疫测定法测定 HCC 患者血浆标本中 β2-GPI 的表达水平,并采用卡方检验或费雪精确检验分析其与临床病理变量的关系。β2-GPI对总生存期(OS)和无病生存期(DFS)的预测意义采用Kaplan-Meier估计法进行评估,差异的统计学意义采用log-rank检验进行评估。Cox比例危险回归模型用于评估OS/DFS时间与临床病理特征之间的关联:结果与非癌症对照组相比,HCC患者的血浆β2-GPI水平明显较低,且与HCC的天冬氨酸氨基转移酶(AST)水平明显相关。高血浆β2-GPI水平与HCC患者较好的OS和DFS明显相关。此外,在多变量分析中发现,血浆β2-GPI表达较高的HCC患者的OS明显较好:结论:HCC 患者血浆中 β2-GPI 蛋白水平升高被认为是预测 OS 和 DFS 改善的独立因素。激活高危人群中的β2-GPI可能是缓解HCC进展的一种有效方法。
{"title":"The Prognostic Significance of Plasma Beta2-Glycoprotein I Levels in Hepatocellular Carcinoma Patients.","authors":"Tsung-Jen Hsieh, Hung-Wei Pan, Yu-Yan Lan, Guan-Ying Hua, Yao-Chun Hsu, Wen-Chin Chiu","doi":"10.21873/cdp.10389","DOIUrl":"10.21873/cdp.10389","url":null,"abstract":"<p><strong>Background/aim: </strong>Beta2-glycoprotein I (β2-GPI) is a plasma glycoprotein with multiple physiological functions, but its relationship with hepatocellular carcinoma (HCC) is still poorly understood. HCC is one of the most common forms of liver cancer and is a leading cause of cancer-related death worldwide. This study aimed to investigate the association between β2-GPI and liver cancer and further validate its potential as a biomarker for HCC.</p><p><strong>Patients and methods: </strong>Thirty-six patients diagnosed with HCC at the Division of Gastroenterology and Hepatology, E-Da Hospital, Taiwan, were included in the study. The expression levels of β2-GPI in plasma specimens from patients with HCC were determined by enzyme immunoassay and analyzed in relation to clinicopathological variables using the Chi-square test or Fisher's exact test. The predictive significance of β2-GPI for both overall survival (OS) and disease-free survival (DFS) was assessed using Kaplan-Meier estimates, and the statistical significance of differences was evaluated through the log-rank test. Cox proportional hazards regression models were used to evaluate the association between OS/DFS time and clinicopathological characteristics.</p><p><strong>Results: </strong>Results: Plasma β2-GPI levels were significantly lower in patients with HCC compared to non-cancer controls and significantly correlated with aspartate aminotransferase (AST) levels of HCC. High plasma β2-GPI levels were significantly associated with better OS and DFS in HCC patients. Furthermore, in multiple variates analyses, OS was found to be significantly better in HCC patients with higher plasma β2-GPI expression.</p><p><strong>Conclusion: </strong>Elevated levels of β2-GPI protein in the plasma of HCC patients were identified as an independent factor predictive of improved OS and DFS. Activating β2-GPI in individuals at high risk could serve as a promising way for mitigating the progression of HCC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"735-742"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy. NOLUS 评分在预测接受新辅助化疗的 HR 阳性 HER2 阴性早期乳腺癌患者的 pCR 和 iDFS 中的作用
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10395
Anna-Lea Amylidi, Loukas Kontovinis, George Douganiotis, Ioannis Natsiopoulos, Konstantinos Papazisis

Background/aim: Breast cancer remains a significant health challenge, with neoadjuvant chemotherapy (NACT) improving clinical outcomes in certain subtypes. However, the role of NACT in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is unclear due to various outcomes and generally low rates of pathologic complete response (pCR). This study introduces the Non-Luminal Disease Score (NOLUS) as a potential predictive tool for assessing the response to NACT in these cases.

Patients and methods: We retrospectively assessed patients diagnosed with locally advanced HR+/HER2- breast cancer who received NACT at our institution from 2009 to 2023. The study explored the association between NOLUS and pCR rates. NOLUS was calculated as positive or negative based on the percentage of estrogen receptor, progesterone receptor, and Ki-67 in tumor cells. We also investigated the correlation between pCR and invasive disease-free survival (iDFS), and examined NOLUS positivity across different age groups.

Results: A total of 149 patients met the inclusion criteria. NOLUS-positive patients exhibited a significantly higher pCR rate of 33.33% compared to 10.4% in NOLUS-negative patients (p=0.0031). With a median follow-up of 2.47 years, NOLUS-positive patients who achieved pCR had a 100% iDFS rate, mirroring the pCR versus residual disease patterns seen in triple-negative patients. NOLUS positivity was observed in 20.43% of patients aged 22-50, compared to 8.93% in those over 50, though this difference was not statistically significant.

Conclusion: NOLUS exhibits potential in predicting pCR in HR+/HER2- breast cancer, serving as a cost-effective substitute for genomic tests.

背景/目的:乳腺癌仍然是一项重大的健康挑战,新辅助化疗(NACT)改善了某些亚型的临床疗效。然而,NACT在激素受体阳性、HER2-阴性(HR+/HER2-)乳腺癌中的作用尚不明确,因为结果各异,病理完全反应(pCR)率普遍较低。本研究将非管腔疾病评分(NOLUS)作为一种潜在的预测工具,用于评估这些病例对 NACT 的反应:我们回顾性评估了2009年至2023年在本院接受NACT治疗的局部晚期HR+/HER2-乳腺癌患者。研究探讨了NOLUS与pCR率之间的关系。NOLUS根据肿瘤细胞中雌激素受体、孕激素受体和Ki-67的百分比计算为阳性或阴性。我们还研究了pCR和无浸润生存期(iDFS)之间的相关性,并考察了不同年龄组的NOLUS阳性率:共有 149 例患者符合纳入标准。NOLUS阳性患者的pCR率为33.33%,明显高于NOLUS阴性患者的10.4%(P=0.0031)。中位随访时间为2.47年,NOLUS阳性患者获得pCR的iDFS率为100%,反映了三阴性患者的pCR与残留疾病模式。在22-50岁的患者中,NOLUS阳性率为20.43%,而在50岁以上的患者中,NOLUS阳性率为8.93%,但这一差异无统计学意义:NOLUS在预测HR+/HER2-乳腺癌的pCR方面具有潜力,可作为基因组检测的一种经济有效的替代方法。
{"title":"The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.","authors":"Anna-Lea Amylidi, Loukas Kontovinis, George Douganiotis, Ioannis Natsiopoulos, Konstantinos Papazisis","doi":"10.21873/cdp.10395","DOIUrl":"10.21873/cdp.10395","url":null,"abstract":"<p><strong>Background/aim: </strong>Breast cancer remains a significant health challenge, with neoadjuvant chemotherapy (NACT) improving clinical outcomes in certain subtypes. However, the role of NACT in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is unclear due to various outcomes and generally low rates of pathologic complete response (pCR). This study introduces the Non-Luminal Disease Score (NOLUS) as a potential predictive tool for assessing the response to NACT in these cases.</p><p><strong>Patients and methods: </strong>We retrospectively assessed patients diagnosed with locally advanced HR+/HER2- breast cancer who received NACT at our institution from 2009 to 2023. The study explored the association between NOLUS and pCR rates. NOLUS was calculated as positive or negative based on the percentage of estrogen receptor, progesterone receptor, and Ki-67 in tumor cells. We also investigated the correlation between pCR and invasive disease-free survival (iDFS), and examined NOLUS positivity across different age groups.</p><p><strong>Results: </strong>A total of 149 patients met the inclusion criteria. NOLUS-positive patients exhibited a significantly higher pCR rate of 33.33% compared to 10.4% in NOLUS-negative patients (p=0.0031). With a median follow-up of 2.47 years, NOLUS-positive patients who achieved pCR had a 100% iDFS rate, mirroring the pCR versus residual disease patterns seen in triple-negative patients. NOLUS positivity was observed in 20.43% of patients aged 22-50, compared to 8.93% in those over 50, though this difference was not statistically significant.</p><p><strong>Conclusion: </strong>NOLUS exhibits potential in predicting pCR in HR+/HER2- breast cancer, serving as a cost-effective substitute for genomic tests.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"775-782"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drainage Fluid Amylase as a Biomarker for the Detection of Anastomotic Leakage After Low Anterior Resection of Rectal Cancer: A Two-center Study. 将引流液淀粉酶作为检测直肠癌低位前切除术后吻合口渗漏的生物标记物:一项双中心研究。
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10399
Yasuhiro Ishiyama, Yasumitsu Hirano, Misuzu Yamato, Sohei Akuta, Masatoshi Yoshizawa, Takatsugu Fujii, Naoto Okazaki, Chikashi Hiranuma, Shinichi Sakuramoto

Aim: This study aimed to investigate the utility of measuring amylase levels in drainage fluid (DFA) for early, non-invasive detection of anastomotic leakage (AL) in undergoing low anterior resection (LAR) for rectal cancer.

Patients and methods: This prospective observational cohort study analyzed drainage fluid samples from patients who underwent LAR for rectal cancer at two medical centers between February 2021 and December 2023. DFA levels were measured on postoperative days (PODs) 1, 3, and 5. AL was confirmed by clinical evidence and radiological imaging. Statistical analyses were performed to evaluate the diagnostic performance of DFA.

Results: Of 120 LAR cases, AL occurred in five (4.16%). DFA levels on POD 3 and 5 were significantly higher in the AL than in the non-AL group (p<0.0001). DFA on POD 5 had the highest diagnostic accuracy for early AL detection, with an area under the curve of 0.99, achieving 100% sensitivity and 99.5% specificity at a cutoff of 846 U/l. A DFA >846 U/l predicted AL with negative predictive and positive predictive values of 83.3% and 100%, respectively, on POD 5.

Conclusion: Measuring DFA is a non-invasive, simple and cost-effective method for early AL detection in patients with rectal cancer undergoing LAR. Our findings also suggested that drain placement may be useful for the early detection of AL through DFA measurement.

目的:本研究旨在探讨测量引流液(DFA)中的淀粉酶水平对早期无创检测直肠癌低位前切除术(LAR)吻合口漏(AL)的实用性:这项前瞻性观察性队列研究分析了 2021 年 2 月至 2023 年 12 月期间在两家医疗中心接受直肠癌 LAR 手术的患者的引流液样本。在术后第 1、3 和 5 天 (POD) 测定 DFA 水平。AL由临床证据和放射成像确认。对 DFA 的诊断性能进行了统计分析:结果:在 120 例 LAR 中,有 5 例(4.16%)发生了 AL。POD3和POD5的DFA水平在AL组明显高于非AL组(P846 U/l预测AL,POD5的阴性预测值和阳性预测值分别为83.3%和100%):在接受 LAR 的直肠癌患者中,测量 DFA 是一种无创、简单且经济有效的早期 AL 检测方法。我们的研究结果还表明,通过测量 DFA,放置引流管可能有助于早期发现 AL。
{"title":"Drainage Fluid Amylase as a Biomarker for the Detection of Anastomotic Leakage After Low Anterior Resection of Rectal Cancer: A Two-center Study.","authors":"Yasuhiro Ishiyama, Yasumitsu Hirano, Misuzu Yamato, Sohei Akuta, Masatoshi Yoshizawa, Takatsugu Fujii, Naoto Okazaki, Chikashi Hiranuma, Shinichi Sakuramoto","doi":"10.21873/cdp.10399","DOIUrl":"10.21873/cdp.10399","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the utility of measuring amylase levels in drainage fluid (DFA) for early, non-invasive detection of anastomotic leakage (AL) in undergoing low anterior resection (LAR) for rectal cancer.</p><p><strong>Patients and methods: </strong>This prospective observational cohort study analyzed drainage fluid samples from patients who underwent LAR for rectal cancer at two medical centers between February 2021 and December 2023. DFA levels were measured on postoperative days (PODs) 1, 3, and 5. AL was confirmed by clinical evidence and radiological imaging. Statistical analyses were performed to evaluate the diagnostic performance of DFA.</p><p><strong>Results: </strong>Of 120 LAR cases, AL occurred in five (4.16%). DFA levels on POD 3 and 5 were significantly higher in the AL than in the non-AL group (p<0.0001). DFA on POD 5 had the highest diagnostic accuracy for early AL detection, with an area under the curve of 0.99, achieving 100% sensitivity and 99.5% specificity at a cutoff of 846 U/l. A DFA >846 U/l predicted AL with negative predictive and positive predictive values of 83.3% and 100%, respectively, on POD 5.</p><p><strong>Conclusion: </strong>Measuring DFA is a non-invasive, simple and cost-effective method for early AL detection in patients with rectal cancer undergoing LAR. Our findings also suggested that drain placement may be useful for the early detection of AL through DFA measurement.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"802-807"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy. 楔形图案是前列腺切除术后接受放疗患者 PSA 复发的预测因素之一
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10386
Masahiro Kawahara, Akira Tanaka, Keiko Akahane, Masashi Endo, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Satoru Takahashi, Michiko Nakamura, Tsuzumi Konishi, Kimitoshi Saito, Satoshi Washino, Tomoaki Miyagawa, Masahiro Hiruta, Hisashi Oshiro, Noriko Oyama-Manabe, Katsuyuki Shirai

Background/aim: In prostate cancer, robotic total prostatectomy is a popular treatment modality. However, prostate-specific antigen (PSA) recurrence after prostate cancer surgery remains a concern. Salvage radiotherapy is commonly used to treat PSA recurrence, but the recurrence rate after salvage radiotherapy is high, highlighting the need for better predictive markers. This study aimed to retrospectively evaluate the association between cribriform pattern and PSA recurrence in patients receiving radiotherapy after radical prostatectomy.

Patients and methods: Data of 50 patients who underwent radiotherapy after total prostatectomy between January 2010 and May 2020 were retrospectively evaluated. The median age was 67 years. Among these patients, two cases involved postoperative irradiation, while 48 cases involved salvage irradiation after postoperative PSA recurrence. The median time from surgery to PSA recurrence was 38.3 months. The median radiation dose was 64 Gy in 32 fractions. Three-dimensional conformal radiation therapy was administered in 38 cases and intensity-modulated radiation therapy was used in 12 cases. Combined hormone therapy was administered in 21 cases. PSA levels were measured every 3 months after treatment. Statistical analysis between groups was performed by a t-test.

Results: The median follow-up period after radiotherapy was 31 months. No local recurrences were observed at the prostate bed, and no deaths related to prostate cancer were recorded during follow-up. However, 18 patients (36.0%) had PSA recurrence. The PSA recurrence rate based on the cribriform pattern was 17.6% in the none to moderate group (34 patients) and 75.0% in the severe cribriform pattern group (16 patients). The PSA recurrence rate was significantly higher in patients with a severe invasive cribriform pattern (p=0.001). No significant differences were observed in other histopathological characteristics.

Conclusion: The cribriform pattern in surgical pathology specimens was found to be a useful predictor of PSA recurrence after postoperative radiotherapy.

背景/目的:对于前列腺癌,机器人全前列腺切除术是一种流行的治疗方式。然而,前列腺癌术后前列腺特异性抗原(PSA)复发仍是一个令人担忧的问题。抢救性放疗通常用于治疗PSA复发,但抢救性放疗后的复发率很高,这凸显了对更好的预测指标的需求。本研究旨在回顾性评估根治性前列腺切除术后接受放疗的患者的楔形花纹与PSA复发之间的关系:回顾性评估了2010年1月至2020年5月期间接受全前列腺切除术后放疗的50名患者的数据。中位年龄为 67 岁。在这些患者中,2例患者接受了术后照射,48例患者在术后PSA复发后接受了挽救性照射。从手术到PSA复发的中位时间为38.3个月。中位放射剂量为64 Gy,分32次照射。38例患者接受了三维适形放射治疗,12例患者接受了调强放射治疗。21例患者接受了联合激素治疗。治疗后每 3 个月测量一次 PSA 水平。组间统计分析采用t检验:放疗后的中位随访时间为 31 个月。结果:放疗后的中位随访期为31个月,未发现前列腺床局部复发,随访期间也没有与前列腺癌相关的死亡记录。然而,有18名患者(36.0%)出现了PSA复发。无至中度组(34 名患者)的 PSA 复发率为 17.6%,重度楔形图案组(16 名患者)的 PSA 复发率为 75.0%。重度浸润性楔形形态患者的 PSA 复发率明显更高(P=0.001)。其他组织病理学特征无明显差异:结论:研究发现,手术病理标本中的ribriform模式是预测术后放疗后PSA复发的有效指标。
{"title":"Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.","authors":"Masahiro Kawahara, Akira Tanaka, Keiko Akahane, Masashi Endo, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Satoru Takahashi, Michiko Nakamura, Tsuzumi Konishi, Kimitoshi Saito, Satoshi Washino, Tomoaki Miyagawa, Masahiro Hiruta, Hisashi Oshiro, Noriko Oyama-Manabe, Katsuyuki Shirai","doi":"10.21873/cdp.10386","DOIUrl":"10.21873/cdp.10386","url":null,"abstract":"<p><strong>Background/aim: </strong>In prostate cancer, robotic total prostatectomy is a popular treatment modality. However, prostate-specific antigen (PSA) recurrence after prostate cancer surgery remains a concern. Salvage radiotherapy is commonly used to treat PSA recurrence, but the recurrence rate after salvage radiotherapy is high, highlighting the need for better predictive markers. This study aimed to retrospectively evaluate the association between cribriform pattern and PSA recurrence in patients receiving radiotherapy after radical prostatectomy.</p><p><strong>Patients and methods: </strong>Data of 50 patients who underwent radiotherapy after total prostatectomy between January 2010 and May 2020 were retrospectively evaluated. The median age was 67 years. Among these patients, two cases involved postoperative irradiation, while 48 cases involved salvage irradiation after postoperative PSA recurrence. The median time from surgery to PSA recurrence was 38.3 months. The median radiation dose was 64 Gy in 32 fractions. Three-dimensional conformal radiation therapy was administered in 38 cases and intensity-modulated radiation therapy was used in 12 cases. Combined hormone therapy was administered in 21 cases. PSA levels were measured every 3 months after treatment. Statistical analysis between groups was performed by a t-test.</p><p><strong>Results: </strong>The median follow-up period after radiotherapy was 31 months. No local recurrences were observed at the prostate bed, and no deaths related to prostate cancer were recorded during follow-up. However, 18 patients (36.0%) had PSA recurrence. The PSA recurrence rate based on the cribriform pattern was 17.6% in the none to moderate group (34 patients) and 75.0% in the severe cribriform pattern group (16 patients). The PSA recurrence rate was significantly higher in patients with a severe invasive cribriform pattern (p=0.001). No significant differences were observed in other histopathological characteristics.</p><p><strong>Conclusion: </strong>The cribriform pattern in surgical pathology specimens was found to be a useful predictor of PSA recurrence after postoperative radiotherapy.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"715-721"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab. 接受曲妥珠单抗治疗的乳腺癌患者发生输液反应的相关因素
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10387
Ryuji Yamaguchi, Masanobu Uchiyama, Motoyasu Miyazaki, Toshinobu Hayashi, Kohei Oyabu, Takafumi Nakano, Koichi Matsuo

Background/aim: Trastuzumab (TRA) is a key drug in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer treatment. Infusion reactions (IR) with TRA are frequently observed in practice. Although the efficacy of premedication has been previously reported, it remains uncommon. The probability of severe IR due to TRA is low; however, when it does occur, it is associated with patient discomfort and expenditure of medical resources. This study aimed to analyze the factors associated with the occurrence of IR in patients with breast cancer who received TRA.

Patients and methods: We retrospectively studied 204 patients who underwent TRA for breast cancer treatment between September 2008 and June 2023, identifying factors influencing the occurrence of IR at the time of TRA administration.

Results: A total of 182 patients were included in this study, and the incidence of IR was 25.8% (47/182 patients). Multiple logistic regression analysis showed that pertuzumab (PER) use, high alkaline phosphatase (ALP), and low high-density lipoprotein (HDL) cholesterol levels were associated with IR.

Conclusion: IR should be considered when PER is combined with TRA. ALP and HDL cholesterol levels may be predictive markers of TRA-induced IR in patients with breast cancer.

背景/目的:曲妥珠单抗(TRA)是治疗人表皮生长因子受体 2 型(HER2)阳性乳腺癌的关键药物。在实践中经常观察到使用 TRA 时出现输注反应(IR)。虽然之前已有关于预处理疗效的报道,但仍不常见。TRA导致严重输液反应的概率很低;然而,一旦发生,就会给患者带来不适并耗费医疗资源。本研究旨在分析接受 TRA 的乳腺癌患者发生 IR 的相关因素:我们对 2008 年 9 月至 2023 年 6 月间接受 TRA 治疗的 204 例乳腺癌患者进行了回顾性研究,找出了影响患者在接受 TRA 治疗时发生 IR 的因素:本研究共纳入 182 例患者,IR 发生率为 25.8%(47/182 例)。多元逻辑回归分析显示,使用百妥珠单抗(PER)、高碱性磷酸酶(ALP)和低高密度脂蛋白(HDL)胆固醇水平与IR有关:结论:PER 与 TRA 联用时应考虑 IR。ALP和高密度脂蛋白胆固醇水平可能是乳腺癌患者TRA诱发IR的预测指标。
{"title":"Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab.","authors":"Ryuji Yamaguchi, Masanobu Uchiyama, Motoyasu Miyazaki, Toshinobu Hayashi, Kohei Oyabu, Takafumi Nakano, Koichi Matsuo","doi":"10.21873/cdp.10387","DOIUrl":"10.21873/cdp.10387","url":null,"abstract":"<p><strong>Background/aim: </strong>Trastuzumab (TRA) is a key drug in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer treatment. Infusion reactions (IR) with TRA are frequently observed in practice. Although the efficacy of premedication has been previously reported, it remains uncommon. The probability of severe IR due to TRA is low; however, when it does occur, it is associated with patient discomfort and expenditure of medical resources. This study aimed to analyze the factors associated with the occurrence of IR in patients with breast cancer who received TRA.</p><p><strong>Patients and methods: </strong>We retrospectively studied 204 patients who underwent TRA for breast cancer treatment between September 2008 and June 2023, identifying factors influencing the occurrence of IR at the time of TRA administration.</p><p><strong>Results: </strong>A total of 182 patients were included in this study, and the incidence of IR was 25.8% (47/182 patients). Multiple logistic regression analysis showed that pertuzumab (PER) use, high alkaline phosphatase (ALP), and low high-density lipoprotein (HDL) cholesterol levels were associated with IR.</p><p><strong>Conclusion: </strong>IR should be considered when PER is combined with TRA. ALP and HDL cholesterol levels may be predictive markers of TRA-induced IR in patients with breast cancer.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"722-728"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-item Modified Frailty Index in Elderly Patients Undergoing Laparoscopic Colorectal Surgery Predicts Postoperative Complications. 腹腔镜结直肠手术老年患者的五项改良虚弱指数可预测术后并发症
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10388
Satomi Okada, Yusuke Inoue, Toshiyuki Adachi, Shinichiro Ito, Tomohiko Adachi, Akihiko Soyama, Kazuma Kobayashi, Masaaki Hidaka, Kengo Kanetaka, Susumu Eguchi

Background/aim: Owing to underlying diseases and decreased physiological functions, frailty in elderly patients may be associated with adverse postoperative complications and mortality. To date, there are various frailty assessment methods, with the five-item modified frailty index (mFI-5) being an objective and concise evaluation tool. This study aimed to clarify whether mFI-5 scoring, a measure of frailty, can predict postoperative outcomes in elderly patients undergoing laparoscopic colorectal surgery.

Patients and methods: A total of 107 patients aged over 80 years who underwent laparoscopic colorectal surgery at Nagasaki University Hospital between 2011 and 2018 were included in this study. The mFI-5 was used to assess the preoperative condition of each patient, with scores compared against various postoperative outcome measures. Univariate analysis was used to determine between-group differences for pre- and post-operative variables.

Results: Of the 107 patients [median age, 83 (80-99) years], 44.9% were male. The mFI-5 score was calculated and patients were divided into three groups: 0 (n=36, 33.6%); 1 (n=44, 41.1%); and 2+ (n=27, 25.3%). The groups were significantly associated with the American Society of Anesthesiology (ASA) classification (p<0.001). Postoperative complications occurred in 43 patients (40.2%), and a higher mFI-5 score was significantly associated with postoperative complications of Clavien-Dindo grade ≥III and duration of hospital stay.

Conclusion: The mFI-5 is an objective and useful tool for predicting postoperative complications of laparoscopic surgery in elderly patients with colorectal cancer.

背景/目的:由于潜在疾病和生理功能下降,老年患者的虚弱可能与不良的术后并发症和死亡率有关。迄今为止,已有多种虚弱评估方法,其中五项改良虚弱指数(mFI-5)是一种客观、简明的评估工具。本研究旨在明确 mFI-5 评分(一种衡量虚弱程度的指标)能否预测接受腹腔镜结直肠手术的老年患者的术后结果:本研究共纳入2011年至2018年期间在长崎大学医院接受腹腔镜结直肠手术的107名80岁以上患者。采用 mFI-5 评估每位患者的术前情况,并将评分与各种术后结果指标进行比较。采用单变量分析确定术前和术后变量的组间差异:107名患者中[中位年龄为83(80-99)岁],44.9%为男性。计算出 mFI-5 评分后,患者被分为三组:0(36 人,占 33.6%);1(44 人,占 41.1%);2+(27 人,占 25.3%)。这些组别与美国麻醉学会(ASA)的分级明显相关(p结论:mFI-5 是预测老年结直肠癌患者腹腔镜手术术后并发症的客观、有用的工具。
{"title":"Five-item Modified Frailty Index in Elderly Patients Undergoing Laparoscopic Colorectal Surgery Predicts Postoperative Complications.","authors":"Satomi Okada, Yusuke Inoue, Toshiyuki Adachi, Shinichiro Ito, Tomohiko Adachi, Akihiko Soyama, Kazuma Kobayashi, Masaaki Hidaka, Kengo Kanetaka, Susumu Eguchi","doi":"10.21873/cdp.10388","DOIUrl":"10.21873/cdp.10388","url":null,"abstract":"<p><strong>Background/aim: </strong>Owing to underlying diseases and decreased physiological functions, frailty in elderly patients may be associated with adverse postoperative complications and mortality. To date, there are various frailty assessment methods, with the five-item modified frailty index (mFI-5) being an objective and concise evaluation tool. This study aimed to clarify whether mFI-5 scoring, a measure of frailty, can predict postoperative outcomes in elderly patients undergoing laparoscopic colorectal surgery.</p><p><strong>Patients and methods: </strong>A total of 107 patients aged over 80 years who underwent laparoscopic colorectal surgery at Nagasaki University Hospital between 2011 and 2018 were included in this study. The mFI-5 was used to assess the preoperative condition of each patient, with scores compared against various postoperative outcome measures. Univariate analysis was used to determine between-group differences for pre- and post-operative variables.</p><p><strong>Results: </strong>Of the 107 patients [median age, 83 (80-99) years], 44.9% were male. The mFI-5 score was calculated and patients were divided into three groups: 0 (n=36, 33.6%); 1 (n=44, 41.1%); and 2+ (n=27, 25.3%). The groups were significantly associated with the American Society of Anesthesiology (ASA) classification (p<0.001). Postoperative complications occurred in 43 patients (40.2%), and a higher mFI-5 score was significantly associated with postoperative complications of Clavien-Dindo grade ≥III and duration of hospital stay.</p><p><strong>Conclusion: </strong>The mFI-5 is an objective and useful tool for predicting postoperative complications of laparoscopic surgery in elderly patients with colorectal cancer.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"729-734"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Subcutaneous Adipose Tissue Radiodensity Predicts Poor Prognosis in Patients With Gastric Cancer. 皮下脂肪组织放射密度高预示胃癌患者预后不良
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10392
Shinichiro Iida, Yasunori Matsumoto, Takeshi Toyozumi, Ryota Otsuka, Tadashi Shiraishi, Hiroki Morishita, Tenshi Makiyama, Yuri Nishioka, Masanari Yamada, Atsushi Hirata, Koichi Hayano, Gaku Ohira, Masayuki Kano, Hisahiro Matsubara

Background/aim: Although the impact of body composition on cancer treatment outcomes of patients with cancer has been increasingly reported, it is still unclear whether the radiodensity of subcutaneous adipose tissue (SAT) on computed tomography (CT) images has a prognostic impact on patients with gastric cancer. We measured muscle and SAT profiles on CT and performed an integrated analysis with clinicopathologic factors.

Patients and methods: We retrospectively analyzed 230 patients with gastric cancer who underwent gastrectomy between June 2016 and December 2020. SAT radiodensity (SAT-R), and skeletal muscle index (SMI) were measured in preoperative CT images. These were compared with clinicopathologic factors, overall survival (OS), and recurrence-free survival (RFS).

Results: High SAT-R was significantly associated with older age (p=0.003) and lower BMI, lymphocyte, hemoglobin, γ-GTP, cholinesterase, albumin, and triglyceride values (p<0.001, <0.001, 0.027, 0.032, <0.001, 0.001, and <0.001, respectively). In the univariate analysis, high SAT-R, and low SMI were significantly associated with poor OS (p=0.003 and <0.001) and poor RFS (p=0.014 and 0.011). In the multivariate analysis by Cox proportional hazard model, high SAT-R and low SMI were identified as independent prognostic factors for poor OS (p=0.037 and 0.007).

Conclusion: High SAT-R on preoperative CT was associated with poor OS in patients with gastric cancer after gastrectomy. SAT-R has a potential to be a novel prognostic marker for surgically treated patients with gastric cancer.

背景/目的:尽管身体成分对癌症患者治疗结果的影响已有越来越多的报道,但目前仍不清楚计算机断层扫描(CT)图像上皮下脂肪组织(SAT)的放射性密度是否对胃癌患者的预后有影响。我们测量了 CT 上肌肉和 SAT 的轮廓,并与临床病理因素进行了综合分析:我们对2016年6月至2020年12月期间接受胃切除术的230例胃癌患者进行了回顾性分析。在术前 CT 图像中测量了 SAT 放射性密度(SAT-R)和骨骼肌指数(SMI)。这些数据与临床病理因素、总生存率(OS)和无复发生存率(RFS)进行了比较:结果:高 SAT-R 与年龄偏大(p=0.003)、体重指数(BMI)、淋巴细胞、血红蛋白、γ-GTP、胆碱酯酶、白蛋白和甘油三酯值偏低(p=0.003)明显相关:术前 CT 上的高 SAT-R 与胃癌患者胃切除术后的不良 OS 有关。SAT-R 有可能成为手术治疗胃癌患者的新型预后标志物。
{"title":"High Subcutaneous Adipose Tissue Radiodensity Predicts Poor Prognosis in Patients With Gastric Cancer.","authors":"Shinichiro Iida, Yasunori Matsumoto, Takeshi Toyozumi, Ryota Otsuka, Tadashi Shiraishi, Hiroki Morishita, Tenshi Makiyama, Yuri Nishioka, Masanari Yamada, Atsushi Hirata, Koichi Hayano, Gaku Ohira, Masayuki Kano, Hisahiro Matsubara","doi":"10.21873/cdp.10392","DOIUrl":"10.21873/cdp.10392","url":null,"abstract":"<p><strong>Background/aim: </strong>Although the impact of body composition on cancer treatment outcomes of patients with cancer has been increasingly reported, it is still unclear whether the radiodensity of subcutaneous adipose tissue (SAT) on computed tomography (CT) images has a prognostic impact on patients with gastric cancer. We measured muscle and SAT profiles on CT and performed an integrated analysis with clinicopathologic factors.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 230 patients with gastric cancer who underwent gastrectomy between June 2016 and December 2020. SAT radiodensity (SAT-R), and skeletal muscle index (SMI) were measured in preoperative CT images. These were compared with clinicopathologic factors, overall survival (OS), and recurrence-free survival (RFS).</p><p><strong>Results: </strong>High SAT-R was significantly associated with older age (p=0.003) and lower BMI, lymphocyte, hemoglobin, γ-GTP, cholinesterase, albumin, and triglyceride values (p<0.001, <0.001, 0.027, 0.032, <0.001, 0.001, and <0.001, respectively). In the univariate analysis, high SAT-R, and low SMI were significantly associated with poor OS (p=0.003 and <0.001) and poor RFS (p=0.014 and 0.011). In the multivariate analysis by Cox proportional hazard model, high SAT-R and low SMI were identified as independent prognostic factors for poor OS (p=0.037 and 0.007).</p><p><strong>Conclusion: </strong>High SAT-R on preoperative CT was associated with poor OS in patients with gastric cancer after gastrectomy. SAT-R has a potential to be a novel prognostic marker for surgically treated patients with gastric cancer.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"754-761"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide. PSA 动力学影响接受恩杂鲁胺治疗的阉割耐药前列腺癌患者的预后。
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10385
Toshiki Oka, Koji Hatano, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Y U Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Norio Nonomura

Background/aim: There is little evidence regarding the predictive value of prostate-specific antigen (PSA) kinetics in patients with castration-resistant prostate cancer treated with an androgen receptor signaling inhibitor. This study investigated the correlation between PSA kinetics and prognosis in patients with castration-resistant prostate cancer treated with enzalutamide.

Patients and methods: We analyzed data from 103 patients who received enzalutamide as primary treatment for castration-resistant prostate cancer at our hospital, focusing on the associations between overall survival and PSA kinetics variables, such as maximal PSA response, PSA nadir, and time to PSA nadir.

Results: The median PSA level at the initiation of enzalutamide was 18.1 ng/ml (interquartile range=7.9-61.2 ng/ml). The median maximal PSA response rate was 88% (interquartile range 55-98), and the median PSA nadir was 1.84 (interquartile range (IQR)=0.38-14.7) ng/ml. The median time to PSA nadir was 19 (IQR=6-28.5) weeks. Maximal PSA response rate <90% [hazard ratio (HR)=2.28, 95% confidence interval (CI)=1.03-5.03, p=0.0413], PSA nadir >2 ng/ml (HR=2.30, 95%CI=1.05-5.07, p=0.0379), time to nadir <19 weeks (HR=2.48, 95%CI=1.15-5.35, p=0.0204) were all independently predictive of shortened overall survival even after adjusting for pre-treatment factors.

Conclusion: Maximal PSA response, PSA nadir, and time to PSA nadir correlated with survival in patients with castration-resistant prostate cancer receiving enzalutamide as a first-line therapy.

背景/目的:几乎没有证据表明前列腺特异性抗原(PSA)动力学对接受雄激素受体信号抑制剂治疗的阉割耐药前列腺癌患者具有预测价值。本研究调查了接受恩杂鲁胺治疗的阉割耐药前列腺癌患者的前列腺特异性抗原(PSA)动力学与预后之间的相关性:我们分析了本院接受恩杂鲁胺作为主要治疗手段的103例阉割耐药前列腺癌患者的数据,重点研究了总生存期与PSA动力学变量(如最大PSA反应、PSA最低点和达到PSA最低点的时间)之间的关系:结果:开始使用恩杂鲁胺时的PSA水平中位数为18.1纳克/毫升(四分位间范围=7.9-61.2纳克/毫升)。PSA最大反应率的中位数为88%(四分位间范围55-98),PSA最低值的中位数为1.84(四分位间范围(IQR)=0.38-14.7)纳克/毫升。达到 PSA 最低值的中位时间为 19(IQR=6-28.5)周。PSA最大反应率为2纳克/毫升(HR=2.30,95%CI=1.05-5.07,P=0.0379),PSA达到最低点的时间 结论:PSA最大反应率为2纳克/毫升,PSA达到最低点的时间为19周(IQR=6-28.5周):接受恩杂鲁胺一线治疗的阉割耐药前列腺癌患者的最大PSA反应、PSA最低点和PSA最低点时间与生存率相关。
{"title":"PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.","authors":"Toshiki Oka, Koji Hatano, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Y U Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Norio Nonomura","doi":"10.21873/cdp.10385","DOIUrl":"10.21873/cdp.10385","url":null,"abstract":"<p><strong>Background/aim: </strong>There is little evidence regarding the predictive value of prostate-specific antigen (PSA) kinetics in patients with castration-resistant prostate cancer treated with an androgen receptor signaling inhibitor. This study investigated the correlation between PSA kinetics and prognosis in patients with castration-resistant prostate cancer treated with enzalutamide.</p><p><strong>Patients and methods: </strong>We analyzed data from 103 patients who received enzalutamide as primary treatment for castration-resistant prostate cancer at our hospital, focusing on the associations between overall survival and PSA kinetics variables, such as maximal PSA response, PSA nadir, and time to PSA nadir.</p><p><strong>Results: </strong>The median PSA level at the initiation of enzalutamide was 18.1 ng/ml (interquartile range=7.9-61.2 ng/ml). The median maximal PSA response rate was 88% (interquartile range 55-98), and the median PSA nadir was 1.84 (interquartile range (IQR)=0.38-14.7) ng/ml. The median time to PSA nadir was 19 (IQR=6-28.5) weeks. Maximal PSA response rate <90% [hazard ratio (HR)=2.28, 95% confidence interval (CI)=1.03-5.03, p=0.0413], PSA nadir >2 ng/ml (HR=2.30, 95%CI=1.05-5.07, p=0.0379), time to nadir <19 weeks (HR=2.48, 95%CI=1.15-5.35, p=0.0204) were all independently predictive of shortened overall survival even after adjusting for pre-treatment factors.</p><p><strong>Conclusion: </strong>Maximal PSA response, PSA nadir, and time to PSA nadir correlated with survival in patients with castration-resistant prostate cancer receiving enzalutamide as a first-line therapy.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"706-714"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin. 对接受恩福单抗韦多汀治疗的晚期尿路上皮癌患者进行风险分类
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10396
Gaku Ishikawa, Yuto Matsushita, Yuichi Kitagawa, Asuka Uchiyama, Yuya Oishi, Hiroki Tanaka, Shinya Watanabe, Eito Suzuki, Shunsuke Watanabe, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Rikiya Matsumoto, Toshiki Ito, Masao Nagata, Toshiyuki Unno, Hiroshi Furuse, Takuji Mizuno, Atsushi Otsuka

Background/aim: Enfortumab Vedotin (EV) is a widely used antibody-drug conjugate for patients with advanced urothelial carcinoma (UC) who have previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors. However, limited information is currently available on prognostic factors and risk classification. Therefore, the present study attempted to identify clinical factors that predict outcomes in patients with advanced UC treated with EV and to develop a novel risk classification model.

Patients and methods: We conducted a multicenter retrospective study including patients with advanced UC treated with EV. Oncological outcomes were assessed using progression-free survival (PFS) and overall survival (OS), and prognostic factors for PFS and OS were investigated. We then examined the usefulness of risk classification based on the prognostic factors identified.

Results: Median PFS and OS were 7.1 and 16.3 months, respectively. High C-reactive protein levels (CRP level ≥0.5 mg/dl) and hypercalcemia (corrected calcium level >10.2 mg/dl) were identified as prognostic factors for PFS (p=0.012 and p=0.003, respectively) and OS (p=0.035 and p<0.001, respectively). We then divided patients into three risk groups: no prognostic factors group, one prognostic factor group, and two prognostic factors group. Significant differences were observed in PFS and OS among the three groups (p<0.001 and p<0.001, respectively) and c-indices were 0.766 for PFS and 0.800 for OS.

Conclusion: The risk classification using CRP and hypercalcemia is useful for predicting the outcomes of patients with advanced UC treated with EV.

背景/目的:恩福妥单抗维多汀(EV)是一种广泛应用的抗体药物共轭物,用于治疗既往接受过铂类化疗和免疫检查点抑制剂治疗的晚期尿路上皮癌(UC)患者。然而,目前有关预后因素和风险分类的信息十分有限。因此,本研究试图找出预测接受EV治疗的晚期UC患者预后的临床因素,并建立一个新的风险分类模型:我们进行了一项多中心回顾性研究,研究对象包括接受EV治疗的晚期UC患者。我们用无进展生存期(PFS)和总生存期(OS)评估了肿瘤结果,并调查了PFS和OS的预后因素。然后,我们根据确定的预后因素研究了风险分类的实用性:中位 PFS 和 OS 分别为 7.1 个月和 16.3 个月。高C反应蛋白水平(CRP水平≥0.5 mg/dl)和高钙血症(校正钙水平>10.2 mg/dl)被认为是PFS(P=0.012和P=0.003)和OS(P=0.035和P=0.003)的预后因素:使用 CRP 和高钙血症进行风险分类有助于预测接受 EV 治疗的晚期 UC 患者的预后。
{"title":"Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin.","authors":"Gaku Ishikawa, Yuto Matsushita, Yuichi Kitagawa, Asuka Uchiyama, Yuya Oishi, Hiroki Tanaka, Shinya Watanabe, Eito Suzuki, Shunsuke Watanabe, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Rikiya Matsumoto, Toshiki Ito, Masao Nagata, Toshiyuki Unno, Hiroshi Furuse, Takuji Mizuno, Atsushi Otsuka","doi":"10.21873/cdp.10396","DOIUrl":"10.21873/cdp.10396","url":null,"abstract":"<p><strong>Background/aim: </strong>Enfortumab Vedotin (EV) is a widely used antibody-drug conjugate for patients with advanced urothelial carcinoma (UC) who have previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors. However, limited information is currently available on prognostic factors and risk classification. Therefore, the present study attempted to identify clinical factors that predict outcomes in patients with advanced UC treated with EV and to develop a novel risk classification model.</p><p><strong>Patients and methods: </strong>We conducted a multicenter retrospective study including patients with advanced UC treated with EV. Oncological outcomes were assessed using progression-free survival (PFS) and overall survival (OS), and prognostic factors for PFS and OS were investigated. We then examined the usefulness of risk classification based on the prognostic factors identified.</p><p><strong>Results: </strong>Median PFS and OS were 7.1 and 16.3 months, respectively. High C-reactive protein levels (CRP level ≥0.5 mg/dl) and hypercalcemia (corrected calcium level >10.2 mg/dl) were identified as prognostic factors for PFS (p=0.012 and p=0.003, respectively) and OS (p=0.035 and p<0.001, respectively). We then divided patients into three risk groups: no prognostic factors group, one prognostic factor group, and two prognostic factors group. Significant differences were observed in PFS and OS among the three groups (p<0.001 and p<0.001, respectively) and c-indices were 0.766 for PFS and 0.800 for OS.</p><p><strong>Conclusion: </strong>The risk classification using CRP and hypercalcemia is useful for predicting the outcomes of patients with advanced UC treated with EV.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"783-788"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Parotid Gland Oncocytoma Mimicking Oropharyngeal Cancer Metastasis: A Case Report from a Radiation Oncologist's Perspective. 模仿口咽癌转移的双侧腮腺肿瘤细胞瘤:放射肿瘤学家眼中的病例报告。
Pub Date : 2024-11-03 eCollection Date: 2024-11-01 DOI: 10.21873/cdp.10401
Seok Ho Lee, Woori Park, Dong Hae Jung

Background/aim: Parotid oncocytomas typically present as benign, unilateral, slow-growing, painless, and solitary masses that are histologically firm and multilobulated. They are often misdiagnosed as pleomorphic adenomas, hemangiomas, or other forms of oncocytosis. However, in our case, the parotid oncocytomas initially mimicked bilateral parotid gland metastasis of advanced oropharyngeal cancer. Here, we present a case of oropharyngeal cancer with bilateral parotid oncocytomas treated with chemoradiotherapy (CCRT).

Case report: We report the case of a 74-year-old man with a sore throat, neck pain, right earache, oropharyngeal cancer, and bilateral parotid gland oncocytoma. Head and neck computed tomography and magnetic resonance imaging (MRI) showed soft-tissue swelling in the right tonsillar fossa and several enlarged level II neck lymph nodes. MRI revealed enhancing masses in both parotid glands, initially suspected to be metastatic lymph nodes. A biopsy of the right palatine tonsil confirmed squamous cell carcinoma with human papilloma virus-16 positivity. A positron emission tomography scan was performed, and biopsy-proven malignant lesions were observed in the right tonsillar region with metastatic lymph nodes in the right and left neck. Focal hypermetabolism was observed in the parotid glands, suspected to be pathological lesions such as metastatic intra-parotid lymph node or Warthin's tumor. An ultrasonography-guided biopsy of the left parotid gland confirmed an oncocytoma. Based on these results, the patient was scheduled for CCRT. After pathological confirmation of parotid oncocytoma, CCRT was administered, excluding the parotid glands within the radiotherapy field.

Conclusion: This is a case of bilateral parotid gland oncocytoma mimicking oropharyngeal cancer.

背景/摘要:腮腺肿瘤细胞瘤通常表现为良性、单侧、生长缓慢、无痛、单发的肿块,组织学上呈坚硬多分叶状。它们经常被误诊为多形性腺瘤、血管瘤或其他形式的肿瘤细胞瘤。然而,在我们的病例中,腮腺肿瘤最初模仿晚期口咽癌的双侧腮腺转移。在此,我们介绍一例口咽癌合并双侧腮腺肿瘤的化疗放疗(CCRT)病例:我们报告了一例74岁男性患者的病例,他患有咽喉痛、颈痛、右耳痛、口咽癌和双侧腮腺肿瘤细胞瘤。头颈部计算机断层扫描和磁共振成像(MRI)显示,右扁桃体窝软组织肿胀,多个颈部二级淋巴结肿大。核磁共振成像显示双侧腮腺有增强肿块,初步怀疑是转移性淋巴结。右侧腭扁桃体活检证实为人乳头状瘤病毒-16阳性的鳞状细胞癌。进行了正电子发射断层扫描,在右扁桃体区域观察到活检证实的恶性病变,左右颈部有转移淋巴结。在腮腺中观察到灶性高代谢,怀疑是腮腺内淋巴结转移或 Warthin's 肿瘤等病理病变。在超声波引导下,对左侧腮腺进行了活检,确诊为肿瘤细胞瘤。根据这些结果,患者被安排接受 CCRT 治疗。病理证实为腮腺肿瘤细胞瘤后,患者接受了CCRT治疗,并将腮腺排除在放疗野之外:这是一例模仿口咽癌的双侧腮腺肿瘤细胞瘤病例。
{"title":"Bilateral Parotid Gland Oncocytoma Mimicking Oropharyngeal Cancer Metastasis: A Case Report from a Radiation Oncologist's Perspective.","authors":"Seok Ho Lee, Woori Park, Dong Hae Jung","doi":"10.21873/cdp.10401","DOIUrl":"10.21873/cdp.10401","url":null,"abstract":"<p><strong>Background/aim: </strong>Parotid oncocytomas typically present as benign, unilateral, slow-growing, painless, and solitary masses that are histologically firm and multilobulated. They are often misdiagnosed as pleomorphic adenomas, hemangiomas, or other forms of oncocytosis. However, in our case, the parotid oncocytomas initially mimicked bilateral parotid gland metastasis of advanced oropharyngeal cancer. Here, we present a case of oropharyngeal cancer with bilateral parotid oncocytomas treated with chemoradiotherapy (CCRT).</p><p><strong>Case report: </strong>We report the case of a 74-year-old man with a sore throat, neck pain, right earache, oropharyngeal cancer, and bilateral parotid gland oncocytoma. Head and neck computed tomography and magnetic resonance imaging (MRI) showed soft-tissue swelling in the right tonsillar fossa and several enlarged level II neck lymph nodes. MRI revealed enhancing masses in both parotid glands, initially suspected to be metastatic lymph nodes. A biopsy of the right palatine tonsil confirmed squamous cell carcinoma with human papilloma virus-16 positivity. A positron emission tomography scan was performed, and biopsy-proven malignant lesions were observed in the right tonsillar region with metastatic lymph nodes in the right and left neck. Focal hypermetabolism was observed in the parotid glands, suspected to be pathological lesions such as metastatic intra-parotid lymph node or Warthin's tumor. An ultrasonography-guided biopsy of the left parotid gland confirmed an oncocytoma. Based on these results, the patient was scheduled for CCRT. After pathological confirmation of parotid oncocytoma, CCRT was administered, excluding the parotid glands within the radiotherapy field.</p><p><strong>Conclusion: </strong>This is a case of bilateral parotid gland oncocytoma mimicking oropharyngeal cancer.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 6","pages":"814-818"},"PeriodicalIF":0.0,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer diagnosis & prognosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1